Compared to the PBS group, both OVs and PD-1/Al@OV treatments significantly increased the number of EdU-positive cells, suggesting that PD-1/Al@OV could inhibit glioma proliferation in vitro (Fig. 4K, Fig. S9B). Here, PDCD1 is linked to central nervous system cancer.